Desai Neel, Albrecht Eric
Department of Anaesthesia, Guy's and St Thomas' NHS Foundation Trust.
King's College London, London, United Kingdom.
Curr Opin Anaesthesiol. 2023 Oct 1;36(5):533-540. doi: 10.1097/ACO.0000000000001272. Epub 2023 Jun 14.
Moderate-to-severe pain is common and remains a significant problem. Compared with opioid analgesia alone, single-shot peripheral nerve blockade has been associated with improved pain relief and the potential of decreased side effects. Single-shot nerve blockade, however, is limited by its relatively short duration of action. In this review, we aim to summarize the evidence related to local anaesthetic adjuncts for peripheral nerve blockade.
Dexamethasone and dexmedetomidine exhibit characteristics that most closely resemble the ideal local anaesthetic adjunct. In upper limb block, dexamethasone has been demonstrated to be superior to dexmedetomidine regardless of administration route for the duration of sensory and motor blockade as well as the duration of analgesia. No clinically significant differences between intravenous and perineural dexamethasone were found. Perineural and intravenous dexamethasone have the potential to prolong sensory blockade to a greater extent than motor blockade. The evidence indicates that the mechanism of action of perineural dexamethasone in upper limb block is systemic in nature. Unlike perineural dexmedetomidine, intravenous dexmedetomidine has not been shown to result in differences in the characteristics of regional blockade compared with local anaesthetic alone.
Intravenous dexamethasone is the local anaesthetic adjunct of choice, increasing the duration of sensory and motor blockade as well as the duration of analgesia by 477, 289 and 478 min, respectively. In view of this, we recommend consideration of the intravenous administration of dexamethasone at a dose of 0.1-0.2 mg/kg for all patients undergoing surgery whatever the level of postoperative pain, mild, moderate or severe. Further research should focus on the potential synergism of action between intravenous dexamethasone and perineural dexmedetomidine.
中重度疼痛很常见,仍然是一个重大问题。与单独使用阿片类镇痛相比,单次外周神经阻滞与更好的疼痛缓解以及潜在的副作用减少有关。然而,单次神经阻滞的作用持续时间相对较短。在本综述中,我们旨在总结与外周神经阻滞局部麻醉辅助剂相关的证据。
地塞米松和右美托咪定具有与理想局部麻醉辅助剂最相似的特性。在上肢阻滞中,无论给药途径如何,地塞米松在感觉和运动阻滞持续时间以及镇痛持续时间方面均已证明优于右美托咪定。静脉注射和神经周围注射地塞米松之间未发现临床显著差异。神经周围和静脉注射地塞米松延长感觉阻滞的程度可能大于运动阻滞。证据表明,上肢阻滞中神经周围注射地塞米松的作用机制本质上是全身性的。与神经周围注射右美托咪定不同,静脉注射右美托咪定与单独使用局部麻醉剂相比,未显示出区域阻滞特征的差异。
静脉注射地塞米松是首选的局部麻醉辅助剂,可分别将感觉和运动阻滞持续时间以及镇痛持续时间延长477、289和478分钟。鉴于此,我们建议无论术后疼痛程度如何,轻度、中度或重度,所有接受手术的患者都考虑静脉注射剂量为0.1-0.2mg/kg的地塞米松。进一步的研究应集中在静脉注射地塞米松和神经周围注射右美托咪定之间潜在的协同作用。